Bone Abstracts

Introduction: Denosumab monoclonal antibody approved for Osteoporosis’s treatment in Europe union and U.S.A. Dose of 60 mg every 6 months reduces the risk of vertebral, non vertebral and hip fractures. What is more increases BMD

Material and methods: Descriptive observational study with densitometric characterisques and risk factors of 64 patients in Osteoporosis unit of HGUG Marañón from November 2011 to December 2013. Analyzing occurrence of new fractures and densitometric change in lumbar spine (LS) and femoral neck (FN) in patients with 3 doses.

Results: Median age: 70.7 years old. 50% had previous fractures, 48% of them with more than 1 fracture. 69.7%vertebral fracture, 24.2% wrist fracture, 9% hip, peroneal, and humerus respectively Basal analytic characteristics: Ca 9.53, P 3.45, PTH 61.13, VitD 30.3 (media de BMD) LS FN.

35.9% received previus treatment with biphophonates, 12.5% with PTH, 4.7% with SERMS, 1.56% renelate of estroncium, 7.8% BF+PTH, 6.25% BF+SERMS and a 31.2% none.

90% with FRAX hip greater than 3%, with an average of 9.4%.

In patients with 3 doses an improvement in DXA at LS was observed in the 100%, with an average of the 11.24%. In FN an improvement in the 75%, with an average of a 4.03%.

The amelioration was higher in patients with previous fractures, but without relation with DXA value.

The tolerance to the treatment was good in the 100%. In none of the patients ocurred new fractures, neither jaw osteonecrosis.

Conclusion: Denosumab antiresortive drug presents an excellent clinical tolerance, as well as a great therapeutic answer in our population.These answer was higher al lumbar spine, which is coincident with previous studies.its a good therapeutic target for osteoporosis.